Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS.

Aberrant splicing of MBD1 produces the MBD1-L isoform, driving myelodysplastic syndromes (MDS) by reshaping the epigenome and causing hematopoietic defects in humans.

• Why it matters: Understanding disease-driving transcripts independent of splicing factor mutations fills a critical gap in MDS research and opens new avenues for targeted therapies.
• What they did: Researchers identified MBD1-L as an MDS-associated isoform driven by reduced WTAP expression, and overexpressed it in healthy human HSPCs to observe MDS-like defects, using multiomics to analyze its epigenetic impact.
• The result: Reversing abnormal MBD1 splicing with nanoparticle-encapsulated antisense oligonucleotides improved erythroid differentiation, highlighting RNA therapies' potential to treat MDS broadly.